{
    "clinical_study": {
        "@rank": "127706", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Series Primary objectives\n\n        -  To demonstrate that the concomitant administration of the hexavalent vaccine with a\n           meningococcal serogroup C conjugate vaccine is non inferior to the administration of\n           the hexavalent vaccine without a MenC vaccine concomitantly in term of seroprotection\n           rate for hepatitis B one month after the third dose of the hexavalent vaccine\n\n        -  To demonstrate that the concomitant administration of a MenC vaccine with the\n           hexavalent vaccine induces an acceptable response for MenC in term of seroprotection\n           rate (SPR) one month after the second dose of MenC\n\n      Booster Primary objectives\n\n      - To describe the immunogenicity of a booster dose of the hexavalent vaccine and of a\n      meningococcal group ACWY conjugate (MenACWY) vaccine either co-administered at 12 months of\n      age or given separately."
        }, 
        "brief_title": "Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neisseria Meningitidis", 
            "Bacterial Infections", 
            "Virus Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Series Secondary objectives\n\n        -  To describe the antibody response to all the hexavalent vaccine antigens one month\n           after the third dose of the hexavalent vaccine when given concomitantly or not to MenC\n\n        -  To describe the antibody response to MenC vaccine when a MenC vaccine is given\n           concomitantly with the hexavalent vaccine, one month after the first and the second\n           dose of MenC vaccine\n\n        -  To describe the safety profile of the hexavalent vaccine after each and any injection\n           when given concomitantly or not with a MenC vaccine\n\n      Booster Secondary objectives\n\n        -  To describe the antibody (Ab) persistence at 12 months of age for the hexavalent\n           valences following a 3-dose primary vaccination at 2, 3 and 4 months of age (prior to\n           administration of a booster dose)\n\n        -  To describe the safety of a booster dose of the hexavalent vaccine and of a\n           meningococcal group ACWY conjugate (MenACWY) vaccine either co-administered at 12\n           months of age or given separately."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy infant 46 to 74 days of age (both inclusive)\n\n          -  Born at full term of pregnancy (\u226537 weeks) and/or with a birth weight\u22652.5 kg\n\n          -  Subject's parent(s) or legal representative able to comply with the study procedures\n\n        Exclusion Criteria:\n\n          -  Participation in another clinical study investigating a vaccine, drug, medical\n             device, or medical procedure\n\n          -  Receipt of any vaccine in the 4 weeks preceding each study vaccination\n\n          -  Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B,\n             poliomyelitis, Haemophilus influenzae type b, meningococcal, pneumococcal, rotavirus\n             infection\n\n          -  Know or suspected congenital, hereditary or acquired immunodeficiency\n\n          -  History of seizures or encephalopathy\n\n          -  Known thrombocytopenia\n\n          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             contraindicating intramuscular injection\n\n          -  Chronic illness that could interfere with trial conduct or completion\n\n          -  Known or suspected hypersensitivity to any of the study vaccines' active substance or\n             excipients or history of a life-threatening reaction to a vaccine(s) containing the\n             same substances as the study vaccines\n\n          -  Contraindication to any of the study vaccines\n\n          -  Known personal or maternal history of hepatitis B or hepatitis C seropositivity\n\n          -  History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus\n             influenzae type b or meningococcal serogroup C infection\n\n          -  Receipt of immune globulin, blood or blood-derived products, immunosuppressive drugs,\n             systemic corticosteroid since birth\n\n          -  Identified as a natural or adopted child of the investigator or employee with direct\n             involvement in the current study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "76 Days", 
            "minimum_age": "46 Days"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839175", 
            "org_study_id": "HXM01C", 
            "secondary_id": "2012-005547-24"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "description": "0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)", 
                "intervention_name": "Hexavalent vaccine", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Diphtheria, tetanus, pertussis, hepatitis B,", 
                    "poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed)."
                ]
            }, 
            {
                "arm_group_label": "Group 1", 
                "description": "0.5 mL intramuscular injection at 2 and 4 months of age", 
                "intervention_name": "NeisVac-C", 
                "intervention_type": "Biological", 
                "other_name": "Meningococcal group C polysaccharide conjugate vaccine adsorbed"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "description": "0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)", 
                "intervention_name": "Prevenar 13", 
                "intervention_type": "Biological", 
                "other_name": "Pneumococcal conjugate vaccine (13-valent, adsorbed)"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "description": "2 mL oral administration at 2, 3 and 4 months", 
                "intervention_name": "RotaTeq", 
                "intervention_type": "Biological", 
                "other_name": "Human-bovine rotavirus reassortants (live) vaccine"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "description": "0.5 mL intramuscular injection at 12 months", 
                "intervention_name": "Nimenrix", 
                "intervention_type": "Biological", 
                "other_name": "Meningococcal group A, C, W-135 and Y conjugate vaccine"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "description": "0.5 mL intramuscular or subcutaneous injection at 13 months of age", 
                "intervention_name": "M-M-RVAXPRO", 
                "intervention_type": "Biological", 
                "other_name": "Measles, mumps and rubella vaccine (live)"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Espoo", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jarvenpaa", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 011"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kokkola", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 010"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pori", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 005"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seinajoki", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 009"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 006"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 007"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vantaa", 
                        "country": "Finland"
                    }, 
                    "name": "Sanofi Pasteur MSD Investigational Site 008"
                }
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Open-label Randomised Study to Evaluate the Immunogenicity and Safety of the Concomitant Administration of a New Hexavalent DTaP-IPV-HepB-PRP-T Combined Vaccine (Hexavalent Vaccine) Given at 2, 3, and 4 Months of Age With a Meningococcal Serogroup C Conjugate (MenC) Vaccine Given at 2 and 4 Months of Age", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of subjects with an anti-hepatitis B concentration \u226510 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-MenC titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with an anti-polyribosylribitol phosphate concentration \u22650.15 \u00b5g/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine), Month 12 (Pre-booster) and Month 13 (One month post-booster)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-diphtheria concentration \u22650.01 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine), Month 12 (Pre-booster)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-tetanus concentration \u22650.01 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine), Month 12 (Pre-booster)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-inactivated poliovirus 1, 2, 3 titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine), Month 12 (Pre-booster) and Month 13 (One month post-booster)"
            }, 
            {
                "measure": "Proportion of subjects with pertussis vaccine response", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-MenC titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 3 (One month after dose 1 of MenC vaccine)"
            }, 
            {
                "measure": "Solicited injection-site and systemic reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 7 following vaccination"
            }, 
            {
                "measure": "Unsolicited adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to Day 30 following vaccination"
            }, 
            {
                "measure": "Serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From signature of the informed consent to the last visit of the subject, an expected average of 11 months"
            }, 
            {
                "measure": "Proportion of subjects with an anti-polyribosylribitol phosphate concentration \u22651 \u00b5g/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 12 (Pre-booster) and Month 13 (One month post-booster)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-diphtheria concentration \u22650.1 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine), Month 12 (Pre-booster) and Month 13 (One month post-booster)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-tetanus concentration \u22650.1 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine), Month 12 (Pre-booster) and Month 13 (One month post-booster)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-MenA, anti-MenC, anti-MenW-135, anti-MenY titre \u22651:8 dil", 
                "safety_issue": "No", 
                "time_frame": "Month 13 (One month after MenAWCY vaccine)"
            }, 
            {
                "measure": "Proportion of subjects with an anti-hepatitis B concentration \u226510 IU/mL", 
                "safety_issue": "No", 
                "time_frame": "Month 12 (Pre-booster) and Month 13 (One month post-booster)"
            }, 
            {
                "measure": "Proportion of subjects with pertussis booster response", 
                "safety_issue": "No", 
                "time_frame": "Month 13 (One month post-booster)"
            }
        ], 
        "source": "Sanofi Pasteur MSD", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sanofi Pasteur MSD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}